GBA1 and Parkinson disease: Thus, on the one hand nizubaglustat, a glucosylceramidase synthesis inhibitor, is in clinical trials for GM1 gangliosidosis, whereas liposomal GM1 is in clinical trials for Parkinson’s disease.